Since there is no approved causative treatment for such cases so far, more attention is being paid to gene therapy, particularly in the case of monogenic epilepsies, e.g., Dravet syndrome related to SCN1A mutations. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.